Live Breaking News & Updates on Janssen Summary

Hits: 143
EMA Confirms Overall Benefit-Risk Profile Remains Positive
Company to update the COVID-19 Vaccine Janssen Summary of Product Characteristics and Package Leaflet to include important information on very rare adverse event
Johnson & Johnson remains committed to supplying 200 million doses of its COVID-19 vaccine to the European Union, Norway and Iceland
NEW BRUNSWICK, NJ, USA I April 20, 2021 I Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company s COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the Company s COVID-19 vaccine. ....

Paul Stoffels , Qi Johnson , Pharmacovigilance Risk Assessment Committee , Us Centers For Disease , European Commission , Drug Administration , Advisory Committee On Immunization Practices , Janssen Pharmaceutical Companies Of Johnson , Europe Following European Medicines Agency , Companies Of Johnson , European Union , European Medicines Agency , European Commission On , Overall Benefit Risk Profile Remains , Janssen Summary , Product Characteristics , Package Leaflet , United Statesi April , Healthcare Professionals , Vice Chairman , Executive Committee , Chief Scientific Officer , Disease Control , Advisory Committee , Immunization Practices , Janssen Pharmaceutical Companies ,